Reflecting on the strength of the community and engagement, Dr. Chaubey said, “Symposium 2026 is a living example of turning possibility into reality – a community united by the desire to be among the ...
XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for ...
Rigel Pharmaceuticals, Inc. ( RIGL) Q4 2025 Earnings Call March 3, 2026 4:30 PM EST Greetings, and welcome to the Rigel Pharmaceuticals Financial Conference Call for the Fourth Quarter and Full Year ...
Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases. Final data from the phase 3 EORTC ...
Dren Bauta returned to school in February after missing nine months. He credits his determination to rejoin his football team as a major motivation. MONTVALE – Dren Bauta couldn’t swallow blueberries.
Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...
Chronic lymphocytic leukemia (CLL), is a type of cancer that affects a type of white blood cell in your body called a lymphocyte. White blood cells are made in your bone marrow and help your body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results